COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02638038
Recruitment Status : Completed
First Posted : December 22, 2015
Last Update Posted : February 28, 2018
Information provided by (Responsible Party):
InteKrin Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 12, 2016
Actual Study Completion Date : December 12, 2016